中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Wenzhou Dry Age-related Macular Degeneration (AMD) Progression Study

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态招聘中
赞助商
The Eye Hospital of Wenzhou Medical University

关键词

抽象

To evaluate the correlation between macular pigment optical density (MPOD) levels and risk of progression in patients with age-related macular degeneration

描述

Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly.[1] The disease is categorized into early, intermediate, or advanced stages based on the severity of symptoms. The advanced stage, including GA and CNV, involves central region of the retina, which leads to a gradual or rapid loss of photoreceptors and central vision.

The macular pigment (MP) consists of xanthophyll, which is formed from the yellow carotenoid lutein, zeaxanthin, and meso-zeaxanthin.These pigments play an important role in protecting the retina against oxidative stress through different mechanisms[6]. Many studies have shown a various association of AMD and MP.Blue Mountain Eye Study revealed low dietary intake of lutein and zeaxanthin is associated with a higher risk of AMD. However, dry and wet subtypes of AMD may have different etiologies and risk factors. Little is known whether longitudinal study of macular pigment optical density (MPOD) is related to AMD progression.

A comprehensive ophthalmologic examination including fundus photography,OCT and MPOD was performed at baseline, and semiannually thereafter for 3 years. Fundus reflectance (VISUCAM 500, reflectance of a single 460 nm wavelength) was used to measure the MPOD levels. Associated risk factors including body-mass index (BMI), smoking, diet, and cardiovascular diseases were documented. Drusen characteristics (size, type, area), pigmentary abnormalities (increased pigment, depigmentation, geographic atrophy), and presence of abnormalities characteristic of neovascular AMD were graded. For estimations of AMD progression , a 9-step severity scale that combines a 6-step drusen area scale with a 5-step pigmentary abnormality scale is used.

In this study, we are going to investigate a 3-year study of incidence and progression for AMD and associated risk factors, in a population-based cohort of Chinese aged 45 years and older living in the city of Wenzhou.

日期

最后验证: 06/30/2019
首次提交: 01/29/2018
提交的预估入学人数: 02/07/2018
首次发布: 02/14/2018
上次提交的更新: 07/16/2019
最近更新发布: 07/17/2019
实际学习开始日期: 12/31/2017
预计主要完成日期: 12/30/2020
预计完成日期: 12/30/2023

状况或疾病

Macular Pigment Optical Density

-

手臂组

干预/治疗
Progressors
Progressors are those individuals with early or intermediate AMD at baseline who progress to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who progress to advanced AMD in both eyes.
Nonprogressor
Nonprogressors are those individuals with early or intermediate AMD at baseline who do not progressed to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who do not progress to advanced AMD in fellow eye.

资格标准

有资格学习的年龄 45 Years 至 45 Years
有资格学习的性别All
取样方式Non-Probability Sample
接受健康志愿者
标准

Inclusion Criteria:

- subject is diagnosed with either CNV, dry AMD

- 45 years of age or older

- provides signed and dated informed consent

Exclusion Criteria:

- Ocular condition in the study eye which may impact vision and confound study outcomes

- Presence of macular edema like retinal vascular diseases or diabetic retinopathy

- active inflammation ofr infection in the study eye

- high myopia( ≥6D )

结果

主要结果指标

1. Association between changes of macular pigment optical density (MPOD) level and incidence rates of advanced AMD [from baseline to month 36]

Incident advanced AMD was evaluated based on the AMD grade at the end of the clinical trial with follow-up time of 3 years. Progressors were those individuals with early or intermediate AMD at baseline who progressed to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who progressed to advanced AMD in both eyes

次要成果指标

1. Association between age and incident Advanced AMD [baseline]

controlling for age (70 years or older versus younger than 70)

2. Association between gender and incident Advanced AMD [baseline]

3. Association between Baseline AMD grade and incident Advanced AMD [baseline]

Baseline AMD grade was defined as AREDS category 1 in both eyes (essentially free of age-related macular abnormalities), category 2 in the worst eye (mild changes including multiple small drusen, nonextensive intermediate drusen, and/or pigment abnormalities), category 3 in the worst eye (at least one large drusen of at least 125µm diameter, extensive intermediate drusen, and/or noncentral geographic atrophy), category 4 in one eye (advanced AMD, either neovascular or central geographic atrophy, or visual loss due to AMD regardless of phenotype), or category 4 in both eyes.

4. Association between cigarette smoking and incident Advanced AMD [baseline]

cigarette smoking information was acquired by questionaires(never, past, or current) .

5. Association between body mass index (BMI) and incident Advanced AMD [baseline]

BMI was calculated as the weight in kilograms divided by the square of the height in meters ( 25, 25-29.9, and 30 )

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge